About us
- About us
- Team
- Investors
Technology
Pipeline
- Pipeline
- About AMD
- PST-611
- PST-809
News & Events
Contact

Month: April 2025

PulseSight Therapeutics: Nonviral Gene Therapy for Dry AMD

Posted on April 16, 2025January 15, 2026 by edgover

PulseSight Therapeutics: Nonviral Gene Therapy for Dry AMD

Posted in In the news

Search

Recent Posts

Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
Targeting Iron in Dry AMD
Research supports that iron dysregulation may drive AMD
PulseSight Therapeutics Publishes Data Supporting Transferrin Therapy for Dry AMD and Geographic Atrophy
Peer Reviewed Publication Provides Evidence for Iron Dysregulation as a Driver of Dry AMD/GA and the Potential of Transferrin to Restore Iron Balance, Reinforcing PulseSight’s Therapeutic Strategy for PST-611

Recent Comments

No comments to show.

Archives

January 2026
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
April 2025
February 2025
January 2025
November 2024
October 2024
September 2024
August 2024
April 2024
March 2024
February 2024

Categories

In the news
Press release

CONTACT US

PRIVACY POLICY

DISCLAIMER

© 2026 PULSESIGHT THERAPEUTICS ALL RIGHTS RESERVED